About Our Company

We are focused on the development of serum based biomarker assays for Multiple Sclerosis. Multiple sclerosis (MS) is the most common disabling neurological condition of young adults, with over 2.5 million patients globally. Treatments are most effective at the early stage of disease, but MS is typically not diagnosed until several years after disease initiation. The current diagnostic biomarker is elevated IgG and oligoclonal bands in the cerebrospinal fluid, but these assays require painful lumbar puncture, are subjective, complex, not reliable for early disease diagnosis or prognosis, and cannot monitor treatment response. There is a great unmet medical need for objective biomarkers for MS patient care. We are focused on developing non-invasive, quantifiable, and simple serum-based MS diagnostic assays.

We are currently testing the feasibility of several biomarkers for MS diagnosis. We have built a strong team consisting of PhD scientists, MS clinicians, statistician and expert in diagnostic assay development to ensure success of the development. We have lab and office space at the Fitzsimons Innovation Campus, with access to all research supplies and equipment.

The goal of next 3 years is to continue validation of the different components of the assays; assessment of patient samples for diagnosis, prognosis and response to therapy; increase sample size to increase significance; standardize the assay, refine and optimize commercial kits, and finally conduct a large preclinical evaluation.

Our Team

Xiaoli Yu
Xiaoli YuCEO, President

Curriculum vitae

Anthony Fringuello
Anthony FringuelloLaboratory Operations Consultant
Jamie Nguyen
Jamie NguyenConsultant

Latest Publications

409, 2013

Varicella Zoster Virus (VZV)-Human Neuron Interaction

September 4th, 2013|Comments Off on Varicella Zoster Virus (VZV)-Human Neuron Interaction

1810, 2011

Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time

October 18th, 2011|Comments Off on Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time

1704, 2011

Identification of peptide targets in neuromyelitis optica

April 17th, 2011|Comments Off on Identification of peptide targets in neuromyelitis optica

1611, 2010

Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF

November 16th, 2010|Comments Off on Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF

More Publications